STAA · STAAR Surgical Company

STAAR Surgical's preliminary first quarter 2026 results show dramatic revenue acceleration, with net sales expected to surpass $90 million, more than doubling from $42.6 million in the prior year period. This growth was primarily fueled by robust performance in China, STAAR's largest market, which accounted for the majority of the increase following a period of constrained shipments in Q1 2025 to allow distributors to work through excess inventory. By quarter-end, China distributor inventory had normalized to the company's targeted range, supporting sustainable refractive market servicing. Continued double-digit growth in the Americas further bolstered results. Management highlighted that the higher sales, paired with a significantly improved cost structure, position the company for meaningful adjusted EBITDA expansion, fulfilling two core objectives from their earlier Shareholder Letter: revenue growth and profit expansion. However, challenges persist in the Middle East and portions of EMEA and APAC, where geopolitical tensions and macroeconomic headwinds led to sales declines; the company warns these could spread if conditions worsen. No forward guidance was provided amid volatile global conditions. Full unaudited results, subject to adjustment post-review, will be disclosed in early May alongside the 10-Q filing. These preliminary figures signal strong business health early in the year, though investors should note the Reg FD disclosure status under Item 7.01 limits its incorporation into other filings.